IMAC Holdings Acquires Theralink Technologies’ Assets in Settlement Arrangement, Withdraws Merger Agreement
On May 6, 2024, IMAC Holdings, Inc. announced that it had acquired the assets of Theralink Technologies, Inc. as part of a Settlement and Release Agreement between the two companies. The acquisition was made in settlement of Theralink’s default on certain outstanding debt. As a result of this development, IMAC Holdings is no longer pursuing its planned merger with Theralink.
On May 1, 2024, IMAC Holdings announced that it had acquired the assets of Theralink Technologies, Inc., including its proteomic analysis and precision medicine expertise. The company has now decided to formally withdraw the Registration Statement on Form S-4 that was related to the now-terminated Merger Agreement with Theralink.
With the acquisition of Theralink’s assets in place, IMAC Holdings is now focused on stabilizing operations and transitioning key employees to capitalize on the success of Theralink’s services in breast cancer diagnostics. Jeff Ervin, CEO of IMAC Holdings stated that he believes this new settlement arrangement will enable Theralink’s services to be commercialized more efficiently and effectively under the umbrella of IMAC Holdings.
IMAC Holdings is a clinical research and commercialization company that specializes in medical advancements and care within the oncology, neurological, and orthopedic fields. For more information about the company or investor inquiries, visit www.imacholdings.com or contact jeff@imacholdings.com respectively
